This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Obesity can be a life-threatening disease because of its association with diabetes mellitus, hypotension, high cholesterol, obstructive sleep apnea, intracranial hypertension (high pressures in the skull), and cardiovascular disease. Roux-en-Y gastric bypass operation is one of the surgical procedures approved by the Food and Drug Administration (FDA) for the treatment of morbid obesity. It is currently the most frequently performed operation for the surgical treatment of obesity in the United States. The broad, long-term goals are to determine effective calcium supplementation and to prevent osteoporosis in patients who have undergone a Roux-en-Y gastric bypass operation as surgical treatment for obesity. This project has two specific aims. The study intends to describe the approximate amount of calcium absorbed from two common calcium supplements, calcium carbonate and calcium citrate, in patients who have undergone Roux-en-Y gastric bypass. This study also intends to analyze whether one of the two calcium supplements is better absorbed than the other after a gastric bypass operation, creating a more positive calcium balance and, consequently, diminishing skeletal bone turn-over. Our central hypothesis is that calcium citrate is better absorbed than calcium carbonate in patients who have been treated for morbid obesity with a Roux-en-Y gastric bypass operation
Showing the most recent 10 out of 693 publications
